Snack smart: 7 powerful health benefits of eating almonds daily
They help regulate blood sugar for people with type 2 diabetes
Their protein and fibre content promote fullness and weight control
Small but mighty in nutrition, almonds are one of the healthiest snacks you can munch on throughout the day. Whether roasted, raw, or soaked, these crunchy nuts pack a punch of wellness in every bite. Here's why making almonds your go-to snack can benefit your body and mind: 1. PACKED WITH HEART-HEALTHY FATS
Almonds are rich in monounsaturated fats, the good kind that helps reduce bad cholesterol (LDL) and increase good cholesterol (HDL). Regular consumption can support heart health and reduce the risk of cardiovascular diseases. 2. HELPS MAINTAIN BLOOD SUGAR LEVELS
With a low glycaemic index and high magnesium content, almonds can help control blood sugar spikes, especially beneficial for people with type 2 diabetes or insulin resistance. 3. SUPPORTS WEIGHT MANAGEMENT
Despite being calorie-dense, almonds are highly satiating. Their combination of protein, fibre, and healthy fats keeps you fuller for longer, helping reduce overall calorie intake and curb junk cravings. 4. BOOSTS BRAIN FUNCTION
Almonds are a good source of vitamin E, folate, and healthy fats that nourish the brain. Regular consumption has been linked to improved memory, sharper focus, and better cognitive function. 5. IMPROVES SKIN AND HAIR HEALTH
Loaded with antioxidants, vitamin E, and essential fatty acids, almonds can help maintain healthy skin by fighting oxidative stress. They also support stronger, shinier hair from the inside out. 6. STRENGTHENS BONES AND TEETH
Almonds contain calcium, phosphorus, and magnesiumâ€'key minerals for maintaining strong bones and healthy teeth. A daily handful can help prevent bone density loss as you age. 7. ENHANCES GUT HEALTH
The fibre content in almonds supports better digestion by feeding the good bacteria in your gut. This promotes a balanced microbiome and can help reduce issues like constipation or bloating.
Whether you're at your desk, travelling, or just need a quick energy boost, almonds make for a smart, nutritious snack. Just a handful a day can support your heart, brain, skin, and moreâ€'naturally and deliciously.
Small but mighty in nutrition, almonds are one of the healthiest snacks you can munch on throughout the day. Whether roasted, raw, or soaked, these crunchy nuts pack a punch of wellness in every bite. Here's why making almonds your go-to snack can benefit your body and mind: 1. PACKED WITH HEART-HEALTHY FATS
Almonds are rich in monounsaturated fats, the good kind that helps reduce bad cholesterol (LDL) and increase good cholesterol (HDL). Regular consumption can support heart health and reduce the risk of cardiovascular diseases. 2. HELPS MAINTAIN BLOOD SUGAR LEVELS
With a low glycaemic index and high magnesium content, almonds can help control blood sugar spikes, especially beneficial for people with type 2 diabetes or insulin resistance. 3. SUPPORTS WEIGHT MANAGEMENT
Despite being calorie-dense, almonds are highly satiating. Their combination of protein, fibre, and healthy fats keeps you fuller for longer, helping reduce overall calorie intake and curb junk cravings. 4. BOOSTS BRAIN FUNCTION
Almonds are a good source of vitamin E, folate, and healthy fats that nourish the brain. Regular consumption has been linked to improved memory, sharper focus, and better cognitive function. 5. IMPROVES SKIN AND HAIR HEALTH
Loaded with antioxidants, vitamin E, and essential fatty acids, almonds can help maintain healthy skin by fighting oxidative stress. They also support stronger, shinier hair from the inside out. 6. STRENGTHENS BONES AND TEETH
Almonds contain calcium, phosphorus, and magnesiumâ€'key minerals for maintaining strong bones and healthy teeth. A daily handful can help prevent bone density loss as you age. 7. ENHANCES GUT HEALTH
The fibre content in almonds supports better digestion by feeding the good bacteria in your gut. This promotes a balanced microbiome and can help reduce issues like constipation or bloating.
Whether you're at your desk, travelling, or just need a quick energy boost, almonds make for a smart, nutritious snack. Just a handful a day can support your heart, brain, skin, and moreâ€'naturally and deliciously. Join our WhatsApp Channel
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News18
20 minutes ago
- News18
NITI Aayog Calls For Quality Overhaul In Pharma, Industry Flags Challenges
Last Updated: Concerns raised included the increasing number of Not of Standard Quality drug alerts, workforce issues and unsustainable drug pricing policies In a high-level consultation led by NITI Aayog on Monday, leading pharmaceutical industry bodies raised pressing concerns over drug quality, regulatory enforcement, and systemic gaps in technical manpower and infrastructure. The meeting, chaired by Dr VK Paul (Member, Health), was aimed at aligning India's pharmaceutical standards with global benchmarks. Held at NITI Aayog headquarters, the central focus was to assess the challenges hampering the production of high-quality, globally acceptable pharmaceutical products, and to chart a strategy for reform. The Niti Aayog, in its invite, mentioned that it aims to discuss the challenges in producing high-quality medicines while also upholding the title of pharmacy to the world. 'A rigorous focus on quality is also essential to ensure patient safety and trust in public health in the domestic market. With a strong network of over 3,000 pharmaceutical companies and approximately 10,500 manufacturing units across the country, it is essential to invest in and uphold the highest quality standards for pharmaceuticals," highlighted the letter sent to various industry associations, including Indian Pharmaceutical Alliance (IPA), Indian Drug Manufacturers' Association (IDMA), Laghu Udyog Bharati, Bulk Drug Manufacturers Association (India), Organisation of Pharmaceutical Producers of India (OPPI), Federation of Pharma Entrepreneurs (FOPE) among others. Industry Flags NSQ and Workforce Issues One of the dominant concerns raised was the increasing number of Not of Standard Quality (NSQ) drug alerts. Industry representatives pointed to poor educational standards in pharmacy colleges, which, they said, result in technically under-qualified personnel who are unable to handle the drug inspectors coming for audit. 'The industry highlighted that the gap in technical competence is directly impacting manufacturing quality," an industry official told News18, requesting anonymity. Representatives from the Confederation of Indian Pharmaceutical Industry (CIPI) highlighted the structural and financial constraints faced by MSMEs, especially in conducting stability studies, a critical requirement for ensuring drug quality. They urged the government to provide financial support for MSMEs to build necessary infrastructure, arguing that this could significantly reduce NSQ cases. The industry also advocated for exclusive engagement meetings between policymakers and MSME associations to address deep-rooted, sector-specific issues that are often overlooked in broader policy discussions. In a strong counter-point, RSS-led Laghu Udyog Bharati challenged the narrative that MSMEs are primarily responsible for quality failures. 'US FDA failure by large corporations is generally overlooked in India and small deviations by micro, small and medium enterprises (MSMEs) are given more attention. This has created a bad image of the MSME industry. Big pharma companies are facing product recalls on a regular basis but no one talks about them," Dr Rajesh Gupta, who represents Laghu Udyog Bharati and supports MSME industry, said. 'The myth of 'Brand Bharat' created by large corporations ignores the fact that MSMEs manufacture and sell 97.3 per cent of India's drugs. Yet, only 2.64 per cent are NSQ-declared, and often with no reported harm to patients," Gupta told Newa18, mentioning that he presented the same argument before the government officials in the meeting. Drug Pricing Pressures: Quality vs Affordability Concerns were also raised around the unsustainable drug pricing policies of the price watchdog, National Pharmaceutical Pricing Authority. Industry participants cautioned the government that low price ceilings have made it unviable for manufacturers to produce quality formulations. As an example, they cited cotrimoxazole, an essential antibiotic, which has reportedly vanished from the domestic market due to pricing stress. 'Government wants us to upgrade quality standards and we will do that. But that comes at a cost. We are investing in technology as well as a skilled workforce. While investments are increasing, we are not allowed to increase prices of products. Hence, we are being pushed to discontinue products," said an industry official part of the meeting. Regulator's Firm Stand on GMP and Accountability Drug Controller General of India Dr Rajeev Singh Raghuvanshi, as per industry sources who were part of the meeting, gave a clear message to the industry, saying: 'There will be no relaxation in enforcement of GMP (Good Manufacturing Practices)." 'Emphasising accountability, he outlined a stricter protocol for handling NSQ cases—companies would now face license suspension after a two-week show-cause notice—with reinstatement only upon satisfactory Corrective and Preventive Action (CAPA) review," said the official quoted above. 'He also expressed disappointment with the role of pharma manufacturing associations, urging them to take more responsibility in ensuring that member units uphold quality norms." top videos View all In the ongoing debate between Indian Pharmacopoeia (IP) and WHO-GMP, the DCGI clarified that the two should be seen as parallel and non-conflicting systems. Overall, Gupta and other industry representatives who attended the meeting told News18 that senior government officials, including DCGI and Dr Paul listened attentively to their concerns. The officials were described as patient and receptive, urging the industry to submit their queries in writing for further consideration. 'Everyone was considerate and gave us ample time to present our concerns," Gupta from LBU said. tags : niti aayog pharma sector VK Paul Location : New Delhi, India, India First Published: July 08, 2025, 10:06 IST News india NITI Aayog Calls For Quality Overhaul In Pharma, Industry Flags Challenges
Hindustan Times
20 minutes ago
- Hindustan Times
Protests in Govandi against BMC's move to private hospitals, demand for better facilities
Mumbai: Over 150 people held a protest from Mankhurd to Govandi on Monday against the privatisation of Lallubhai Compound Multispeciality and Shatabdi hospitals, and also demanded to improve the services, functionality and the diagnostic facilities of the hospitals. The protestors marched from Mankhurd to Govandi demanding to halt privatisation. (Raju Shinde) This comes after the Brihanmumbai Municipal Corporation (BMC) has decided to partially privatise six hospitals in Mumbai under the Public-Private Partnership (PPP) model and issued tenders to the hospitals. About 150 to 200 people including progressive youth groups, doctors, political activists and resident associations staged a large-scale protest under the umbrella of the 'Save Hospital, Stop Privatisation' action committee alongside the residents of M-East ward (including Govandi, Deonar, Mankhurd, Shivaji Nagar, Cheetah Camp and a part of Chembur) starting at Lallubhai compound in Mankhurd, moving up to the ward office in Govandi. With nearly 80% of the population living in slums, the underprivileged residents of the ward depend on Lallubhai Compound Multispeciality and Shatabdi hospitals in Govandi for their treatment. 'The majority of the citizens of the M-East division live in slums, and do not even have regular nutritious food supply. In this context, effective government public health services become a matter of life and death,' said Baban Thake, Mumbai coordinator of Revolutionary workers party of India, a part of the committee. The committee demanded that the corporation scrap the tenders. They also demanded to increase the functionality of ICUs and NICUs in maternity homes within 30 days, start the services of Maharashtra Nagar Maternity Home immediately and also set up free diagnostic centres within the next one month. The committee also suggested that the corporation to organise monthly meetings to address public grievances. Many residents who participated in the protest were affected personally by the lack of healthcare in the region. Kavitha Modliyar, a resident of Mankhurd, said, 'The laboratories are not functional, there are no beds or staff members, none of the hospitals have medications. With further privatisation, the costs will only increase. How are we supposed to pay for this? The poor will only die going forward.' 'Shockingly, life expectancy here is just 39 years here, owing to the maternal deaths, malnourishment, Tuberculosis cases, respiratory illnesses such as asthma induced by the Deonar dumping ground,' said Thake. The group shouted slogans such as 'Stop Privatisation of Hospitals! Hospitals are for public need! Not for corporate greed!' walking towards the ward office with passersby joining in. After reaching the ward office, the protestors waited outside the office for two hours, demanding to speak to the additional municipal commissioner of health vehemently and put forward their demands. The BMC on March 5, released a tender to privatise Lallubhai hospital's operations. On June 13, a similar tender was issued to Shatabdi hospital, including a plan to introduce a 100-seat private medical college in the hospital. According to the tenders issued in March, Shatabdi hospital and medical college, currently with 581 beds, will be run by a private entity with 70% beds reserved for patients paying for their treatment and only 30% for patients referred by the corporation at 'concessional rates'. For Lallubhai Compound Multispeciality Hospital, the 410-bed hospital is proposed to be handed over to a private institution on a PPP basis, with only 150 beds reserved for the patients of the Municipal Corporation, while the remaining 260 beds will be reserved for the economically weaker sections based on possession of an orange or yellow ration card. Dr. Abhay Shukla, health expert and National co convenor, Jan Swasthya Abhiyan, whose Mumbai wing Jan Arogya Abhiyan was present at the scene, said that at present, there are 20 hospitals already under the PPP model in the corporation limits and added, 'These need to be reviewed immediately before deciding to introduce more such models. The hospitals under PPP have doctors on contractual basis with no accountability, nor are they trained to handle the ICU cases. The quality of care is significantly compromised in such hospitals. This is a serious problem that we are challenging. Corporation hospitals can at least be held accountable.' Additional municipal commissioner Dr Vipin Sharma did not respond to the messages or calls by Hindustan Times.
News18
20 minutes ago
- News18
Wegovy Makes Strong Debut, Mounjaro Leads As Weight Loss Drug Market Heats Up
Last Updated: The booming uptake of anti-obesity drugs in India is further underscored by rising momentum of Eli Lilly's Mounjaro, which has shown a sharp month-on-month increase in consumption Blockbuster weight loss drug Wegovy, developed by Novo Nordisk, officially entered the Indian pharmaceutical market in the last week of June and ended up registering strong sales of Rs 2.53 crore in its first week, data shows. According to the data by pharma research firm Pharmatrak, a total of 1,788 units were sold across five dosage strengths, indicating a swift adoption among prescribers and patients alike. Wegovy's sales data is for the period between June 24 and June 30. The Danish drugmaker's Wegovy is available in five dosage strengths ranging from 0.25 mg to 2.4 mg, administered via prefilled syringes. While the recommended starting dose for the new drug is 0.25 mg, sales data shows an unusual trend with strong demand across all dose strengths, suggesting prior patient exposure or rapid titration. 'The medication follows a titration schedule, with doses increasing every four weeks. However, data reveals that all strengths have seen uptake from the start, suggesting some patients may have previously been on semaglutide therapy through imported channels even before the drug's formal rollout in India," Sheetal Sapale, vice-president (commercial), Pharmatrak, told News18. Top endocrinologists agreed that while some patients were already importing Wegovy or Ozempic for consumption, the others are probably transitioning from oral semaglutide tablet Rybelsus to injectable Wegovy now. 'Some patients were already importing Ozempic or Mounjaro," said Dr Anoop Misra, chairman at Fortis C-DOC Centre of Excellence for Diabetes, Metabolic Diseases and Endocrinology. Dr Ambrish Mithal, chairman and head, endocrinology and diabetes at Max Healthcare, pointed at another possibility. 'While many people were already importing and consuming, there will be a subset of people who must be trying to transition from oral tablets to injectable semaglutide. Rybelsus was already available in India and many people were consuming it already and now probably, they are shifting to injectable doses. In this case, they can start from medium doses such as 0.5 mg or 1mg." Wegovy V/s Mounjaro The booming uptake of anti-obesity drugs in India is further underscored by the rising momentum of Eli Lilly's Mounjaro (tirzepatide), which has shown a sharp month-on-month increase in consumption, with over 37,000 units sold in June, data shows. The report by Pharmatrak suggests strong adherence to prescribed dosing schedules and parallel onboarding of new patients. Tirzepatide, despite launching just a quarter ago, has already captured 8 per cent market share, joining semaglutide (Wegovy's active ingredient) to collectively dominate 75 per cent of the anti-obesity drug market by value. According to the data, the overall anti-obesity segment has grown nearly five-fold in five years, driven by better awareness, affordability, and willingness to try newer GLP-1-based therapies, compared to older agents like Orlistat that had limited efficacy and acceptability in the Indian context.
